PanoramaTM

Non-invasive prenatal testing (NIPT)

Panorama is a blood-based genetic, prenatal screening test of the pregnant mom that screens for common chromosomal conditions that affect a baby’s health. Panorama uses unique SNP*-based technology to deliver the most accurate non-invasive prenatal testing on the market.

Panorama can be performed as early as nine weeks gestation. Most results will be returned to your doctor within 5-7 calendar days.

*SNP, single nucleotide polymorphism

Contact us

The only SNP-based NIPT delivers more insights and greater accuracy

PanoramaTM is:

  • the most rigorously validated NIPT
  • the only NIPT that distinguishes mother’s DNA from baby’s DNA
  • the approach that creates unique, clinically validated capabilities
  • Panorama evaluates SNPs— the 1% of our DNA that makes us different from one another

A trusted resource

  • Validated in SMART, the largest prospective NIPT study with over 20,000 participants enrolled.
  • More than 3 million women in more than 60 countries have chosen Panorama for genetic testing during pregnancy.
  • Panorama has been evaluated in 25 peer-reviewed publications and in more than 1.3 million pregnancies.
  • Panorama offers complimentary pre- and post-test information sessions with board-certified genetic counselors.
  • Panorama poses no risk to the baby compared to amniocentesis or chorionic villus sampling (CVS).

SMART

SNP-based microdeletion and aneuploidy registry

Patients
20000+

studied

Sites
21

global centers

Results
100%

of patients included in analysis had genetic confirmation

The largest prospective NIPT study

Panorama is a screening test, which means that this test does not make a final diagnosis. A high-risk result means that your pregnancy could be at risk for a specific genetic condition. However, you cannot know for sure if your baby has that condition based on screening results alone. All medical decisions should be made after discussion with your clinician regarding diagnostic testing during the pregnancy, like amniocentesis or chorionic villus sampling (CVS), or testing the baby after birth.

Panorama offers prenatal screening for twin, egg donor, and surrogate pregnancies.

Conditions screened in twin, egg donor, and surrogate pregnancies:

  • Trisomy 21
  • Trisomy 18
  • Trisomy 13
  • Sex chromosome trisomies (reported when seen)*
  • 22Q11.2 deletion syndrome (optional)*

*Identical twins only

Conditions Screened For

Panorama prenatal genetic testing screens for common genetic conditions that are caused by extra or missing chromosomes in the baby’s DNA. Because Panorama uses a unique technology to truly distinguish between the mother’s and the baby’s DNA, it is the only NIPT that tests for triploidy, and it has the highest accuracy in determining the sex of the baby (optional). Some conditions, such as Down syndrome, are caused by extra copies of a specific chromosome. Others, such as microdeletions, occur when a chromosome is missing a small piece of genetic information. Microdeletions affect pregnancies equally, regardless of maternal age.

TRISOMIES

TRISOMY 21 (DOWN SYNDROME)

TRISOMY 18 (EDWARDS SYNDROME)

TRISOMY 13 (PATAU SYNDROME)

SEX CHROMOSOME ABNORMALITIES

MONOSOMY X (TURNER SYNDROME)

KLINEFELTER SYNDROME

TRIPLE X SYNDROME

JACOB'S SYNDROME

MICRODELETIONS*

22Q11.2 DELETION SYNDROME

PRADER-WILLI SYNDROME

ANGELMAN SYNDROME

1P36 DELETION SYNDROME

CRI-DU-CHAT SYNDROME

TRIPLOIDY

ONLY NIPT THAT TESTS FOR TRIPLOIDY

*Not available for egg-donor or surrogate pregnancies or in cases of dizygotic (non-identical twins)

Specifications

Complete Test Specifications

Overall test specification for PanoramaTM

The information in the table below relates to the general performance of the test.

Sensitivity is the ability to correctly identify a truly high risk case as high risk. For example, in a group of Trisomy 21 cases, Panorama will correctly identify more than 99% of those cases.

Specifity is the ability correctly identify an unaffected case as low risk.

Positive Predictive Value is the likelihood the result says high-risk and the fetus is actually affected. For example, when Panorama shows a high-risk result for Trisomy 21, there is a 91% chance that the fetus is affected by Trisomy 21. In other words, 9% of the time, you may get a high-risk result when the fetus is not affected by trisomy 21.

Negative Predictive Value is the likelihood the result says lowrisk and the fetus is truly not affected.

Condition
Sensitivity (95%CI)
Specificity (95% CI)
PPV
NPV
Trisomy 21 1,2,3,4
>99% (CI 97,8-99,9)
>99,9% (CI 99,7-100)
95%
>99,99%*
Trisomy 181,2,3,4
98,2% (CI 90,4-99,9)
>99,9% (CI 99,7-100)
91%
>99,99%*
Trisomy131,2,3,4
>99% (CI 87,2%-100)
>99,9% (CI 99,8-100)
68%
>99,99%*
Monosomy X1,2,3,4
94,7% (CI 74,0-99,9)
>99,9% (CI 99,7-100)
78%
>99,99%*
Tripolidy5,6
>99,9% (CI 66,4-100)
>99,9% (CI 99,5-100)
5,3%
>99,99%*
XXX, XXY, XYY4 **
73,1% (CI 61,0-85,1)
>99,9% (CI 99,90-99,99)
86,4%
99,87%
22q11.2 deletion syndrome7,8,9
83,3% (CI 51,6-97,9)
>99,9% (CI 99,91-99,98)
53%***
99,9% (CI 99,9-100)****
1p36 deletion syndrome7,8
>99% (CI 2,5-100)
>99,9% (CI 99,1-100)
7-17%****
99,98-99,99%****
Angelman-syndrome7,8
95,5% (CI 77,2-99,9)
>99,9% (CI 99,1-100)
10%***
>99,99%
Cri-du-Chat-syndrome7,8
>99% (CI 85,8-100)
>99,9% (CI 99,1-100)
2-5****
>99,99%
Prader-Willi-syndrome7,8
93,8 (CI 69,8-99,8)
>99,9% (CI 99,1-100)
5%
>99,99%
Female
>99,9% (CI 99,4-100)
>99,9% (CI 99,5-100)
Male
>99,9% (CI 99,5-100)
>99,9% (CI 99,4-100)

* A clinical follow-up study is underway to control a decrease in NPV below the specified endpoint, but follow-up is not performed in all low-risk cases
** Sex chromosome-related abnormalities are only reported if a high risk is detected.
*** PPV values ​​for DiGeorge and Angelman syndromes are 53% and 10%, respectively, based on published data in cases without ultrasound abnormalities, but after ultrasound abnormalities prior to the test, PPV is 100% for both diseases.
**** Fetal fraction The above test specifications are only applicable to single and identical twin pregnancies.

1 DDar et al.Am J Obstet Gynecol. Epub prior to publication. https://doi.org/10.1016/j.ajog.2022.01.019
2 DiNonno W et al. J Clin Med. 2019. 26:8(9);1311.doi: https://doi.org/10.3390/jcm8091311
3 Nicolaides et al. Fetal Diagn Ther. 2014;35(3):212-7.
4 Curnow KJ et al. Am J Obstet Gynecol. 2015. 212(1):79.e1-9.doi: https://doi.org/10.1016/j.ajog.2014.10.012
5 Martin K et al. ISPD 25th International Conference: June, 2021
6 Dar et al. Am J Obstet Gynecol. Epub prior to publication. https://doi.org/10.1016/j.ajog.2022.01.002
7 Martin K et al. Clin Genet. 2018. 93(2):293-300. doi: https://doi.org/10.1111/cge.13098
8 Wapner RJ et al. Am J Obstet Gynecol. 2015. 212(3):332e1-9.d doi: https://doi.org/10.1016/j.ajog.2014.11.041

Contact us!

Is PanoramaTM right for you?

We're here to help you find out!

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

The tests described have been developed and their performance characteristics determined by the CLIA-certified laboratory performing the test. The tests have not been cleared or approved by the US Food and Drug Administration (FDA). Although FDA is exercising enforcement discretion of premarket review and other regulations for laboratory-developed tests in the US, certification of the laboratory is required under CLIA to ensure the quality and validity of the tests. CAP accredited, ISO 13485 certified, and CLIA certified. © 2022 Natera, Inc. All Rights Reserved.